Search

Your search keyword '"Fichtenbaum, Carl J."' showing total 32 results
Start Over Author "Fichtenbaum, Carl J." Publisher lippincott williams & wilkins
32 results on '"Fichtenbaum, Carl J."'

3. Associations of Muscle Density and Area With Coronary Artery Plaque and Physical Function.

Author

Erlandson, Kristine M., Umbleja, Triin, Lu, Michael T., Taron, Jana, Ribaudo, Heather J., Overton, Edgar T., Presti, Rachel M., Haas, David W., Sax, Paul E., Yin, Michael T., Zhai, Bingxue Kris, Louis, Rochelle, Upadhyay, Namrata, Eslami, Parastou, Douglas, Pamela S., Zanni, Markella V., Fitch, Kathleen V., Fulda, Evelynne S., Fichtenbaum, Carl J., and Malvestutto, Carlos D.

Published
2023
Full Text
View/download PDF

4. Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV.

Author

Douglas, Pamela S., McCallum, Sara, Lu, Michael T., Umbleja, Triin, Fitch, Kathleen V., Foldyna, Borek, Zanni, Markella V., Fulda, Evelynne S., Bloomfield, Gerald S., Fichtenbaum, Carl J., Overton, Edgar T., Aberg, Judith A., Malvestutto, Carlos D., Burdo, Tricia H., Arduino, Roberto C., Ho, Ken S., Yin, Michael T., Ribaudo, Heather J., and Grinspoon, Steven K.

Published
2023
Full Text
View/download PDF

5. Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV.

Author

Overton, Edgar T., Weir, Isabelle R., Zanni, Markella V., Fischinger, Stephanie, MacArthur, Rodger D., Aberg, Judith A., Fitch, Kathleen V., Frank, Michael, Albrecht, Helmut, Goodenough, Elliot, Rhame, Frank S., Fichtenbaum, Carl J., Bloomfield, Gerald S., Malvestutto, Carlos, Supparatpinyo, Khuanchai, McCallum, Sara, Douglas, Pamela S., Alter, Galit, Ribaudo, Heather, and Grinspoon, Steven K.

Published
2022
Full Text
View/download PDF

7. Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Author

Bloomfield, Gerald S., Weir, Isabelle R., Ribaudo, Heather J., Fitch, Kathleen V., Fichtenbaum, Carl J., Moran, Laura E., Bedimo, Roger, de Filippi, Christopher, Morse, Caryn G., Piccini, Jonathan MHS, Zanni, Markella V., Lu, Michael T., Hoffmann, Udo, Grinspoon, Steven K., and Douglas, Pamela S.

Published
2022
Full Text
View/download PDF

9. Endovascular Therapy for Patients With Acute Ischemic Stroke During the COVID-19 Pandemic: A Proposed Algorithm.

Author

Smith, Matthew S., Bonomo, Jordan, Knight IV, William A., Prestigiacomo, Charles J., Richards, Christopher T., Ramser, Evan, Adeoye, Opeolu, Bertsch, Stuart, Shirani, Peyman, Vagal, Achala, Fichtenbaum, Carl J., Housholder, Anne, Khatri, Pooja, Kleindorfer, Dawn O., Broderick, Joseph P., Grossman, Aaron W., and Knight, William A 4th

Published
2020
Full Text
View/download PDF

22. Leptin Replacement Therapy But Not Dietary Polyunsaturated Fatty Acid Alleviates HIV Protease Inhibitor-Induced Dyslipidemia and Lipodystrophy in Mice.

Author

Riddle, Tara M., Fichtenbaum, Carl J., and Hui, David Y.

Subjects
*FATTY acids, *LEPTIN, *WHIPPLE'S disease, *FATTY degeneration, *LIVER diseases, *THERAPEUTICS
Abstract

Examines the effectiveness of polyunsaturated fatty acid diet or leptin replacement therapy on ritonavir-induced dyslipidemia, lipodystrophy and liver steatosis. Ability of leptin replacement therapy to reduce the ritonavir-induced interscapular fat mass and improve liver steatosis.

Published
2003
Full Text
View/download PDF

26. Bacteremia in hospitalized pateints infected with the human immunodeficiency virus: A case-...

Author

Fichtenbaum, Carl J. and Claiborne Dunagan, W.

Subjects
*HIV infection complications, *BACTEREMIA
Abstract

Examines cases of non-mycobacterial bacteremias in patients infected with human immunodeficiency viruses (HIV) in Rhode Island over a 2-year period. Study of the risk factors associated with its occurrence; Intravenous catheter-related sites of infection; Mortality rates in bacteremic patients with or without HIV infection.

Published
1995
Full Text
View/download PDF

28. Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV.

Author

Lake JE, Taron J, Ribaudo HJ, Leon-Cruz J, Utay NS, Swaminathan S, Fitch KV, Kileel EM, Paradis K, Fulda ES, Ho KS, Luetkemeyer AF, Johnston CD, Zanni MV, Douglas PS, Grinspoon SK, Lu MT, and Fichtenbaum CJ

Subjects
Female, Humans, Male, Middle Aged, Primary Prevention, Adult, Aged, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Cardiovascular Diseases complications, HIV Infections complications, HIV Infections drug therapy, HIV Infections epidemiology, Metabolic Syndrome complications, Metabolic Syndrome epidemiology, Non-alcoholic Fatty Liver Disease complications, Non-alcoholic Fatty Liver Disease epidemiology
Abstract

Background: Hepatic steatosis, including nonalcoholic fatty liver disease (NAFLD), is common among people with HIV (PWH). We present baseline steatosis prevalence and cardiometabolic characteristics among REPRIEVE substudy participants., Methods: REPRIEVE is an international, primary cardiovascular disease prevention, randomized, controlled trial of pitavastatin calcium vs. placebo among 7769 PWH ages 40-75 years on antiretroviral therapy (ART) and with low-to-moderate cardiovascular risk. A subset of participants underwent noncontrast computed tomography, with hepatic steatosis defined as mean hepatic attenuation less than 40 HU or liver/spleen ratio less than 1.0, and NAFLD defined as steatosis in the absence of frequent alcohol use or viral hepatitis., Results: Of 687 evaluable persons, median age was 51 years, BMI 27 kg/m 2 , CD4 + T-cell count 607 cells/μl; 17% natal female sex, 36% Black, 24% Hispanic, and 98% HIV-1 RNA less than 400 copies/ml. Hepatic steatosis prevalence was 22% (149/687), and NAFLD 21% (96/466). Steatosis/NAFLD prevalence was higher in men and with older age, non-Black race, and higher BMI and waist circumference. Both were associated with BMI greater than 30 kg/m 2 , metabolic syndrome components, higher atherosclerotic cardiovascular disease (ASCVD) risk score, HOMA-IR, LpPLA-2 and hs-CRP, and lower high-density lipoprotein cholesterol. Of HIV-specific/ART-specific characteristics, only history of an AIDS-defining illness was more common among persons with steatosis/NAFLD. After adjusting for age, sex and race/ethnicity, BMI greater than 30 kg/m 2 , HOMA-IR greater than 2.0, Metabolic syndrome and each of its components were associated with NAFLD prevalence., Conclusion: In this cohort with controlled HIV and low-to-moderate cardiovascular risk, hepatic steatosis and NAFLD were common and associated with clinically relevant metabolic and inflammatory disturbances but not current HIV-related or ART-related factors., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

30. Effects of HIV infection and antiretroviral therapy on the heart and vasculature.

Author

Dubé MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, and Fisher SD

Subjects
American Heart Association, Blood Vessels drug effects, Blood Vessels virology, Cardiovascular Diseases chemically induced, Cardiovascular Diseases virology, HIV Infections drug therapy, Heart drug effects, Heart virology, Humans, United States, Anti-Retroviral Agents adverse effects, Cardiovascular Diseases etiology, HIV Infections complications
Published
2008
Full Text
View/download PDF

31. A truvada hypersensitivity reaction simulating abacavir hypersensitivity.

Author

de Perio MA, Gomez FJ, Frame PT, and Fichtenbaum CJ

Subjects
Adolescent, Anti-Retroviral Agents therapeutic use, Deoxycytidine adverse effects, Deoxycytidine therapeutic use, Drug Combinations, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, HIV-1, Humans, Male, Organophosphorus Compounds therapeutic use, Anti-Retroviral Agents adverse effects, Deoxycytidine analogs & derivatives, Drug Hypersensitivity etiology, HIV Infections drug therapy, Organophosphorus Compounds adverse effects
Published
2007
Full Text
View/download PDF

32. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

Author

Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, and Aweeka F

Subjects
Adult, Anticholesteremic Agents adverse effects, Atorvastatin, Drug Interactions, Heptanoic Acids adverse effects, Human Experimentation, Humans, Pravastatin adverse effects, Pyrroles adverse effects, Simvastatin adverse effects, Anticholesteremic Agents pharmacokinetics, HIV Protease Inhibitors pharmacokinetics, HIV Seronegativity, Heptanoic Acids pharmacokinetics, Pravastatin pharmacokinetics, Pyrroles pharmacokinetics, Ritonavir pharmacokinetics, Saquinavir pharmacokinetics, Simvastatin pharmacokinetics
Abstract

Objective: Lipid lowering therapy is used increasingly in persons with HIV infection in the absence of safety data or information on drug interactions with antiretroviral agents. The primary objectives of this study were to examine the effects of ritonavir (RTV) plus saquinavir soft-gel (SQVsgc) capsules on the pharmacokinetics of pravastatin, simvastatin, and atorvastatin, and the effect of pravastatin on the pharmacokinetics of nelfinavir (NFV) in order to determine clinically important drug-drug interactions., Design: Randomized, open-label study in healthy, HIV seronegative adults at AIDS Clinical Trials Units across the USA., Methods: Three groups of subjects (arms 1, 2, and 3) received pravastatin, simvastatin or atorvastatin (40 mg daily each) from days 1-4 and 15-18. In these groups, RTV 400 mg and SQVsgc 400 mg twice daily were given from days 4-18. A fourth group (arm 4) received NFV 1250 mg twice daily from days 1-14 with pravastatin 40 mg daily added from days 15-18. Statin and NFV levels were measured by liquid chromatography/tandem mass spectrometry., Results: Fifty-six subjects completed both pharmacokinetic study days. In arms 1-3, the median estimated area under the curves (AUC)(0-24) for the statins were: pravastatin (arm 1, n = 13), 151 and 75 ng.h/ml on days 4 and 18 (decline of 50% in presence of RTV/SQVsgc), respectively (P = 0.005); simvastatin (arm 2, n = 14), 17 and 548 ng.h/ml on days 4 and 18 (increase of 3059% in the presence of RTV/SQVsgc), respectively (P < 0.001); and total active atorvastatin (arm 3, n = 14), 167 and 289 ng.h/ml on days 4 and 18 (increase of 79% in the presence of RTV/SQVsgc), respectively (P < 0.001). In arm 4, the median estimated AUC(0-8) for NFV (24 319 versus 26 760 ng.h/ml; P = 0.58) and its active M8 metabolite (15 565 versus 14 571 ng.h/m; P = 0.63) were not statistically different from day 14 to day 18 (without or with pravastatin)., Conclusions: Simvastatin should be avoided and atorvastatin may be used with caution in persons taking RTV and SQVsgc. Dose adjustment of pravastatin may be necessary with concomitant use of RTV and SQVsgc. Pravastatin does not alter the NFV pharmacokinetics, and thus appears to be safe for concomitant use.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results